It is also interesting to

note that age of symptom onset varied widely in patients carrying the pathogenic hexanucleotide expansion, including some individuals who developed weakness in their ninth decade of life. The genetic and/or environmental factors underlying this variability remain to be determined. Our development of a rapid, reliable method of screening individuals for the repeat expansion will have immediate clinical utility by allowing early identification of ALS patients at increased risk of cognitive impairment, and of FTD cases at increased risk Selleck BMS 754807 of progressive paralysis. In the longer term, the identification of the genetic lesion underlying chromosome 9p21-linked ALS and FTD, together with the observed high frequency in these patient populations, makes it an ideal target for drug development aimed at amelioration of the disease process. Broadly speaking, pathogenic repeat expansions are thought to cause disease through haploinsufficiency, in which

expression or splicing of the target gene is perturbed, or through the generation of abnormal amounts of toxic RNA that disrupt normal cellular pathways. We favor the second as a mechanism in chromosome 9 FTD/ALS, given the large DAPT order size of the Calpain expansion visualized by FISH and its noncoding localization within the C9ORF72 gene. RNA generated from such pathogenic repeat expansions are thought to disrupt transcription by sequestering normal RNA and proteins involved in transcription regulation ( Wojciechowska and Krzyzosiak, 2011), and disruption of RNA metabolism has already been implicated in the pathogenesis of ALS associated with

mutations in TDP-43 and FUS ( Lagier-Tourenne et al., 2010). Interestingly, an index family studied previously demonstrating aberrant RNA metabolism of an astroglial gene, EAAT2, ( Lin et al., 1998) is in fact a chromosome 9 hexanucloitude mutation carrier. This might provide early evidence that aberrant RNA metabolism occurs as part of the pathogenic mechanism. However, knowing the pattern of distribution of C9ORF72 expression is likely to be key in understanding cell vulnerability and local expression of the hexanucleotide repeat expansion, which is probably influenced by the promoter of the C9ORF72 gene. We did not find consistent differences in expression between cases and controls. This may represent the true biological effect of the GGGGCC hexanucleotide repeat expansion on C9ORF72 expression, or alternatively it may reflect the small number of samples analyzed or tissue-to-tissue variation in expression of this gene.